Sibel Oyucu Orhan

Dr. Sibel Oyucu Orhan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
SOSibel Oyucu Orhan
Sibel Oyucu Orhan
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
ECErdem Cubukcu
Erdem Cubukcu
ADadem deligonul
adem deligonul
BOBirol Ocak
Birol Ocak
TETürkkan Evrensel
Türkkan Evrensel
Kaposi sarcoma is a rare disease and there is a gap in the literature about which chemotherapeutics should be applied, especially for the classical type. We aimed to present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 Kaposi sarcoma (KS) patients treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics, and the chemotherapeutic agents administered to the 16 KS patients diagnosed in our center and treated with chemotherapy, based on the medical records obtained. The median age, gender, type of KS, site of involvement, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4–85.8 years). Among the patients, 1 had immunosuppression-related KS, 4 had AIDS-related KS, and 11 had classical KS. In the first-line cytotoxic therapy, 7 patients received pegylated-liposomal doxorubicin (PLD), 6 patients received paclitaxel, 2 patients received oral etoposide, and 1 patient received the adriamycin, bleomycin, and vincristine regimen. In the Kaplan–Meier analysis, the PFS was 39.9 months (95% CI, 7.7–72.0). In the first-line setting, a significant difference in terms of PFS was observed between the PLD- and paclitaxel-treated groups (not reached vs. 12.8 months, p = 0.033). The OS was 66.1 months (95% CI, 30.2–102.0). The ORR of the 16 patients was 43.8%, and their DCR was 81.3%. No grade 3 or 4 toxicity was observed. This retrospective study showed that PLD seems better than paclitaxel in terms of PFS and response rates and it has shown to have a good safety profile in KS patients.

13 December 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SSSeda Sali
Seda Sali
CACandan Demiröz Abakay
Candan Demiröz Abakay
MSMürsel Sali
Mürsel Sali
HGHakan Güdücü
Hakan Güdücü
FÇFahri Güven Çakır
Fahri Güven Çakır
ECErdem Cubukcu
Erdem Cubukcu
Background and Objectives: Nasopharyngeal carcinoma (NPC) displays marked geographic and histopathological heterogeneity, and prognostic determinants in non-endemic regions remain incompletely defined. This study aimed to evaluate the impact of clinicopathological characteristics and treatment modalities on survival outcomes among patients with stage II–IVA NPC treated with curative intent at a single tertiary cancer center. Materials and Methods: A retrospective analysis was conducted on 81 consecutive patients with histologically confirmed NPC treated between 2000 and 2022. Demographic, clinical, and treatment parameters were extracted from institutional records. Survival outcomes—including disease-free survival (DFS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS)—were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic variables identified in univariate analysis were further assessed by multivariable Cox proportional hazards regression (Cox’s model). Results: The cohort included 59 men (72.8%) and 22 women (27.2%), with a median age of 50.8 years (range, 19–78). Most patients presented with locally advanced disease (T3–T4, 53.1%; N2, 60.5%; stage III–IVA, 87.7%). Non-keratinizing undifferentiated carcinoma (World Health Organization [WHO] type III) was the predominant histology (71.6%), followed by the non-keratinizing differentiated subtype (17.3%). Median DFS and OS were 94.6 and 139.4 months, respectively. According to the univariate analysis, histological subtypes and a family history of cancer were significantly associated with DFS, whereas comorbid systemic disease showed an unexpected association with longer DMFS. The multivariable Cox model identified the histological subtype as an independent predictor of disease recurrence (HR = 2.23, 95% CI: 1.00–4.94; p = 0.049). For OS, both histological subtype (HR = 2.40, 95% CI: 1.10–5.25; p = 0.029) and age at diagnosis (HR = 1.05, 95% CI: 1.02–1.09; p = 0.005) were independent adverse prognostic factors. Conclusions: In this long-term, single-center study from a non-endemic region, histological subtype emerged as the most powerful determinant of prognosis, significantly influencing both DFS and OS. Patients with non-keratinizing undifferentiated (WHO type III) carcinoma demonstrated superior outcomes compared with those with differentiated histology. Additionally, increasing age at diagnosis was independently associated with poorer OS. In contrast, inflammatory and nutritional biomarkers, the Pan-Immune–Inflammation Value (PIV) and the Prognostic Nutritional Index (PNI), showed no prognostic significance. These findings underscore the continued prognostic relevance of histopathologic classification and age and highlight the need for large-scale, standardized studies integrating Epstein–Barr virus (EBV) status and host-related factors in non-endemic NPC populations.

10 September 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SOSibel Oyucu Orhan
Sibel Oyucu Orhan
BOBedrettin Orhan
Bedrettin Orhan
ŞEŞeyma Esenbuğa
Şeyma Esenbuğa
SSSeda Sali
Seda Sali
BCBurcu Caner
Burcu Caner
ECErdem Cubukcu
Erdem Cubukcu
Background and Objectives: Advanced solid organ tumors, particularly breast, lung, and prostate cancers, frequently metastasize to bone, leading to debilitating skeletal-related events (SREs). Denosumab, a RANKL inhibitor, is crucial in preventing SREs. This study aimed to comparatively evaluate the efficacy and adverse effect profiles of denosumab in patients with bone metastases originating from these three common cancer types. Materials and Methods: This retrospective study included 146 patients treated with denosumab for bone metastases. Data on demographics, SREs before and during denosumab treatment, serum creatinine, calcium, and magnesium levels (at baseline, 3, and 6 months), other adverse effects, and survival were analyzed. Results: Before denosumab, SREs were present in 36.3% of patients (breast: 43.4%, prostate: 28%, lung: 33.8%). During denosumab treatment, SRE rates markedly decreased across all groups (breast: 9.4%, prostate: 16.0%, lung: 8.8%), with no significant intergroup difference in on-treatment SREs. Significant decreases in serum calcium levels were observed at 3 and 6 months post-denosumab initiation in breast (p < 0.0001) and lung cancer patients (p = 0.001). Mean creatinine levels significantly decreased in lung (p < 0.0001) and prostate (p = 0.020) cancer patients at 3 and 6 months. Overall survival significantly differed, with lung cancer patients having the shortest median survival (p < 0.005). Conclusions: Denosumab effectively reduces the incidence of SREs in patients with bone metastases from breast, lung, and prostate cancer. However, clinicians must diligently monitor for hypocalcemia, a notable adverse effect, particularly at 3 and 6 months after starting denosumab, with specific caution warranted in patients with lung cancer.

16 August 2018 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
SOSibel Oyucu Orhan
Sibel Oyucu Orhan
TATektemur Ahmet
Tektemur Ahmet
NGNEVZAT GOZEL
NEVZAT GOZEL
IÖİbRahim Hanifi Özercan
İbRahim Hanifi Özercan
SYServet Yolbas
Servet Yolbas
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Background/aim: Insulin-like growth factor (IGF)-I is a differentiation and growth factor. Antifibrotic action of octreotide has been reported in pulmonary fibrosis. The present study aimed to research the prophylactic and therapeutic potential of octreotide on a bleomycin (BLM)-induced experimental scleroderma model. Materials and methods: Sixty Balb/c female mice were divided into 6 groups. Daily subcutaneous BLM (100 mu g) was injected for 3 weeks in groups II and III and for 6 weeks in groups V and VI. Octreotide (100 mu g/kg per day) was injected subcutaneously for the first 3 weeks in group III (prophylactic) and the second 3 weeks in group VI (therapeutic). Mice in groups I, II, and III were sacrificed at the end of the third week, while mice in groups IV, V, and VI were sacrificed at the end of the sixth week. Results: Repeated BLM applications increased dermal inflammatory cell counts and dermal thickness, and led to dermal fibrosis at both the third and sixth weeks. Moreover, mRNA expressions of TG F-beta 1 and IGF binding protein (IGFBP)-3 and -5 were higher in the BLM-injected sham groups. On the other hand, IGFBP-3 and -5 mRNA expressions were significantly decreased in both the prophylactic and therapeutic octreotide groups. Similarly, octreotide decreased dermal inflammatory infiltrations and dermal thickness. Conclusion: Octreotide has antifibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I plays pathogenic roles, and octreotide is a candidate for research in the treatment of scleroderma.

30 June 2025 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
PDF file
SKSeda Kahraman
Seda Kahraman
MHMutlu Hızal
Mutlu Hızal
ÖGÖzge Gümüşay
Özge Gümüşay
GBGül Başaran
Gül Başaran
MSMustafa Seyyar
Mustafa Seyyar
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

4 August 2025 in The Oncologist
Verified
Journal Article
Open access
SSSeda Sali
Seda Sali
MSMürsel Sali
Mürsel Sali
BCBurcu Caner
Burcu Caner
BOBirol Ocak
Birol Ocak
ECEyup Coban
Eyup Coban
TETürkkan Evrensel
Türkkan Evrensel
Background: Neuroendocrine neoplasms (NEN) originate in many body parts, with 70% reported from the gastrointestinal system, 25% from the lungs. NENs of the breast account for < 1% of all NENs. The primary breast NEN nomenclature was changed in the most recent World Health Organization classification in 2019. Since the pathological classification has changed several times, there are no definitive data on treatment management. Methods: In this study, patients followed up in our clinic were pathologically reevaluated according to the latest classification. Results: The clinical characteristics, treatments, recurrence, and survival status of 36 patients with early stage primary breast NEN were examined. A statistically significant difference was determined in respect of overall survival (OS) for the Eastern Cooperative Oncology Group Performance Score (ECOG PS), type of surgery, age ≥ 70 years, PR positivity, and tumor size. A low ECOG PS, younger age, breast-conserving surgery (BCS), and small tumor diameter were associated with better survival. A low ECOG PS, early stage, BCS, and fewer than 4 malignant lymph nodes were associated with better disease-free survival. All the patients in this study were at an early stage and were treated for typical breast cancer, although some patients diagnosed with neuroendocrine carcinoma (NEC) received cisplatin and etoposide treatment. Conclusions: In our study, the prognosis of breast NEN patients was better than the literature data. Maybe the prognosis of patients evaluated as breast NEN according to the new classification is better than the older classification groups.